Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as cediranib, Cediranib
cediranib and olaparib · 1 trial · 1 indication
The ORR was defined as the percentage of patients with objective response (complete response \[CR\] or partial response \[PR\]) according to RECIST 1.1 and was assessed by ICR. Only patients whose CR/PR response was confirmed by a second scan at least 4 weeks after the initial response, with no evidence of progression between the initial and CR/PR confirmation visit were included. CR: Disappearance of all target lesions (TLs) and non-TLs (NTLS) since baseline; any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 millimeters (mm). PR: At least a 30% decrease in the sum of the diameters of TL, referencing the baseline sum of diameters. Data obtained up until progression, or last evaluable assessment in the absence of progression were included in the assessment of ORR.
| Arm | Type | Description |
|---|---|---|
| combination of cediranib and olaparib | EXPERIMENTAL | Open label |
| Name | Type | Description |
|---|---|---|
| cediranib and olaparib | DRUG | Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily Dose reduction for both products is allowed |
Inclusion Criteria: 1. Ability and willingness to provide written informed consent, and to comply with the requirements of the protocol 2. Females aged ≥18 years with previous histologically proven diagnosis of high grade serous, high grade endometroid or clear cell ovarian cancer, fallopian tube o...
Cediranib is an investigational small molecule being studied in oncology. It has been evaluated in advanced solid tumors, recurrent platinum resistant ovarian cancer, metastatic colorectal cancer, advanced solid malignancies, and recurrent glioblastoma. Clinical trials have also explored its use in bowel obstruction and ovarian, fallopian tube, and primary peritoneal cancers.
Cediranib is a kinase inhibitor, belonging to the -nib class of drugs. It works by inhibiting kinase enzymes involved in tumor growth and blood vessel formation. This mechanism is being studied across multiple solid tumor types, including ovarian cancer and colorectal cancer.
Cediranib is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has sponsored clinical trials of Cediranib across various cancer indications.
Cediranib is in Phase 2 clinical development. It has completed Phase 1 and Phase 3 trials, but it remains investigational and has not been approved by regulatory authorities. The drug is still being studied for safety and efficacy in cancer patients.
Cediranib has been studied in several clinical trials. NCT00399035 was a Phase 3 trial in metastatic colorectal cancer with 1254 participants. NCT00750425 and NCT00981721 were Phase 1 pharmacokinetic studies in advanced solid tumors. NCT07648745 was a Phase 2 trial in platinum-resistant ovarian cancer.
Yes, Cediranib is also known as RECENTIN and AZD2171. The Phase 3 colorectal cancer trial NCT00399035 referred to Cediranib as AZD2171 and RECENTIN. These names refer to the same investigational drug developed by AstraZeneca.